drugset
drugset / Trial / NCT05654077

EBV CAR-T Cells for Nasopharyngeal Carcinoma

NCT05654077 ↗

Phase 0 Unknown 24 enrolled The Affiliated Hospital of Xuzhou Medical University Guangzhou Bioresette Biomedical Technology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to investigate the safety and preliminary efficacy of EBV CAR-T cells in the treatment of relapsed/refractory NPC

Timeline

Start
2022-01-18
Primary completion
2022-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CAR-T Cell Injection Cell therapy 3e+06 cells/kg Intravenous
Subject CAR-T Cell Injection Cell therapy 9e+06 cells/kg Intravenous
Subject CAR-T Cell Injection Cell therapy 1.5e+07 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 250 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 350 mg/m2 Intravenous
Background Fludarabine Small molecule 25 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous

Indications

nasopharyngeal carcinoma